Polynovo Limited (AU:PNV)
ASX:PNV
Want to see AU:PNV full AI Analyst Report?
PNV Stock Chart & Stats
AU$1.01
AU$0.01(0.49%)
At close: 4:00 PM EST
AU$1.01
AU$0.01(0.49%)
Day’s Range― - ―
52-Week RangeAU$0.87 - AU$1.67
Previous CloseN/A
Volume733.50K
Average Volume (3M)1.48M
Market Cap
AU$704.66M
Enterprise ValueAU$703.73M
Total Cash (Recent Filing)AU$29.26M
Total Debt (Recent Filing)AU$31.74M
Price to Earnings (P/E)73.1
Beta1.72
Next Earnings
Aug 21, 2026EPS Estimate
0.01Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.01
Shares Outstanding690,843,000
10 Day Avg. Volume1,478,953
30 Day Avg. Volume1,476,427
Financial Highlights & Ratios
PEG Ratio0.42
Price to Book (P/B)9.95
Price to Sales (P/S)6.51
P/FCF Ratio-76.87
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
AU$1.56Price Target Upside54.46% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)<0.01
Revenue Forecast (FY)AU$150.68M
Bulls Say, Bears Say
Bulls Say
Revenue Growth & Market DiversificationSustained double‑digit, geographically broad growth indicates durable clinical adoption of NovoSorb. Recurring procedure‑linked sales across >800 accounts and faster RoW expansion reduce customer concentration and support a multi‑year organic revenue runway as indications and penetration deepen.
High Gross Margins & Improving ProfitabilityExceptionally high gross margins reflect proprietary polymer economics and pricing power, enabling strong margin retention as volumes scale. Rising EBIT/EBITDA demonstrates operational leverage, supporting reinvestment in R&D and commercial expansion while helping absorb timing one‑offs.
Manufacturing Capacity ExpansionA validated facility with ~5x prior capacity materially increases supply flexibility and lowers unit costs long term. Greater capacity supports multiple SKUs and outpatient sizes, reduces previous production constraints, and underpins scalable commercial rollouts and margin sustainability as demand ramps.
Bears Say
Weak Cash Generation & FCF ConversionLow operating cash conversion and a steep negative free cash flow trend limit the company's ability to self‑fund trials, reimbursement studies and commercial expansion. Persistent weak cash generation increases reliance on external funding, raising dilution or leverage risk during scale‑up phases.
Outpatient Reimbursement UncertaintySecuring office‑based reimbursement hinges on CMS decisions and potentially costly RCTs. This structural barrier could delay or restrict outpatient adoption, meaningfully limiting addressable market expansion and postponing high‑volume, lower‑cost care settings that drive recurring consumable sales.
Market/tender Complexity And Demand LumpyComplex tendering in markets like India and inherently lumpy large‑burn case incidence create persistent revenue timing volatility. This complicates predictable scale, tightens forecasting accuracy and slows the pace at which high‑opportunity markets contribute materially to sustained growth.
Polynovo News
PNV FAQ
What was Polynovo Limited’s price range in the past 12 months?
Polynovo Limited lowest share price was AU$0.86 and its highest was AU$1.67 in the past 12 months.
What is Polynovo Limited’s market cap?
Polynovo Limited’s market cap is AU$704.66M.
When is Polynovo Limited’s upcoming earnings report date?
Polynovo Limited’s upcoming earnings report date is Aug 21, 2026 which is in 61 days.
How were Polynovo Limited’s earnings last quarter?
Polynovo Limited released its earnings results on Feb 20, 2026. The company reported AU$0 earnings per share for the quarter, missing the consensus estimate of AU$0.006 by -AU$0.006.
Is Polynovo Limited overvalued?
According to Wall Street analysts Polynovo Limited’s price is currently Undervalued.
Does Polynovo Limited pay dividends?
Polynovo Limited does not currently pay dividends.
What is Polynovo Limited’s EPS estimate?
Polynovo Limited’s EPS estimate is 0.01.
How many shares outstanding does Polynovo Limited have?
Polynovo Limited has 690,843,000 shares outstanding.
What happened to Polynovo Limited’s price movement after its last earnings report?
Polynovo Limited reported an EPS of AU$0 in its last earnings report, missing expectations of AU$0.006. Following the earnings report the stock price went down -8.458%.
Which hedge fund is a major shareholder of Polynovo Limited?
Currently, no hedge funds are holding shares in AU:PNV
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Polynovo Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
AU$1.56 (54.46% Upside)
AU$1.56 (54.46% Upside)
Blogger Sentiment
Bullish
AU:PNV Sentiment 97%
Sector Average ―
Sector Average ―
Insider Transactions
Bought Shares
Worth AU$140.4K over
the Last 3 Months
the Last 3 Months
Technicals
SMA
Negative
20 days / 200 days
Momentum
-33.28%
12-Months-Change
Fundamentals
Return on Equity
11.87%
Trailing 12-Months
Asset Growth
17.90%
Trailing 12-Months
Company Description
Polynovo Limited
PolyNovo Limited is an innovative developer of medical devices, operating across key international markets including the United States, Australia, New Zealand, the United Kingdom, Ireland, and Singapore. The company's primary offering is the NovoSorb Biodegradable Temporising Matrix (BTM), a product engineered to facilitate the physiological closure of clean, surgically debrided wounds. Beyond this, PolyNovo is actively advancing a pipeline of new technologies, such as devices for hernia repair and tissue reinforcement, the NovoSorb Dermal Beta Cell Implant designed to house pancreatic islets within the skin, and various NovoSorb drug elution depots. Originally founded in 1998, the entity was known as Calzada Limited until it rebranded to PolyNovo Limited in November 2014. Its corporate headquarters are located in Port Melbourne, Australia.
PNV Company Deck
PNV Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call presents a predominantly positive operational and commercial picture: double‑digit revenue growth across major regions (group +26%, U.S. +25.3%, RoW +28.3%), rapid MTX adoption (~+193%), improved cash flow (+$9.0M) and a strong clinical evidence base (348 studies). Key strategic catalysts (PMA submission, SynPath outpatient pathway, expanded manufacturing capacity, recruitment of a Chief Scientific Officer) provide clear upside. Short‑term headwinds include a timing‑related manufacturing variance (~$3.6–3.7M) from planned slowdowns, an R&D lab fire asset write‑off (insured), FX translation losses, and reimbursement/regulatory uncertainty for outpatient CMS coverage which may require an RCT. Management frames several negatives as one‑offs or timing issues and expects margin and free cash flow improvement in H2. Overall, highlights materially outweigh the lowlights.View all AU:PNV earnings summariesPNV Stock 12 Month Forecast
Average Price Target
AU$1.56
▲(54.46% Upside)
Technical Analysis
Nova Eye Medical
―
Cochlear
―
Micro-X Ltd.
―
Aroa Biosurgery Ltd
―
EBR Systems, Inc. Shs Chess Depository Interests Repr 1 Sh
―
Options Prices
Currently, No data available
---